Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andy Smith

Latest From Andy Smith

Stock Watch: When Governments Step In

Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.

Stock Watch Advisory Committees

Stock Watch: 2022 Starts Badly For Biotech

A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.

Stock Watch Clinical Trials

Stock Watch: Bridgebio’s Endpoint A Bridge Too Far

The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.

Stock Watch Research & Development

Stock Watch: The Pandemic Brings Christmas Presents

While the Omicron variant does not bode well for 2022, vaccine boosters and oral antivirals are the products from the pharmaceutical sector that should keep on giving. Even if partisan analysts choose to forget them.

Stock Watch Pricing Debate

Stock Watch: Can Acadia’s Rett Syndrome Drug Succeed?

In a rare disease indication, clinical trial efficacy in Phase III should be the ticket to successful sales. But safety issues warrant careful consideration.

Stock Watch Drug Safety

Stock Watch: Hedging The Effects Of Omicron

As well as hedging investors’ portfolios against the effects of pandemic waves, the stock prices of Pfizer and Merck & Co seem to be negatively correlated to each other, just as their pandemic-related revenues are to their traditional drug sales.

Stock Watch Coronavirus COVID-19
See All
UsernamePublicRestriction

Register